Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: Two years' experience

Antonio Molina-Carballo, Antonio Muñoz-Hoyos, Russel J Reiter, Miguel Sánchez-Forte, Francisco Moreno-Madrid, Miguel Rufo-Campos, Juan Antonio Molina-Font, Darío Acuña-Castroviejo

Research output: Contribution to journalArticle

156 Citations (Scopus)

Abstract

Recent data indicate that melatonin inhibits brain glutamate receptors and nitric oxide production, thus suggesting that it may exert a neuroprotective and antiexcitotoxic effect. Melatonin has been seen to prevent seizures in several animal models and to decrease epileptic manifestations in humans. The lack of response to conventional anticonvulsants in an epileptic child led us to use melatonin in this case. A female child who began to have convulsive seizures at the age of 1.5 months and was diagnosed as having severe myoclonic epilepsy was unsuccessfully treated with different combinations of anticonvulsants, including valproic acid, phenobarbital, clonazepam, vigabatrin, lamotrigin, and clobazam. Melatonin was thus added to the treatment. Imaging studies (CT, SPECT, and MNR), EEG recordings, blood biochemical, and hematological analyses, including measures of the circadian rhythm of melatonin, were made. The child was initially treated with various anticonvulsants. Severe neurological and psychomotor deterioration combined with increased seizure activity showed a lack of response to the treatment. At the age of 29 mon the patient was in a pre-comatose stage at which time melatonin was added to treatment. After 1 month of melatonin plus phenobarbital therapy and for a year thereafter, the child's seizures were under control. On reducing the melatonin dose after this time, however, seizures resumed and the patient's condition was re-stabilized after restoring melatonin. Prior to our attempts to reduce melatonin, all analyses, including EEG recordings and SPECT, were normal. As far as the results of neurological examination are concerned, only mild hypotony without focalization remained. Changes in the therapeuticschedules during the second year of melatonin treatment, including the withdrawal of phenobarbital, did not result in the same degree of seizure control, although progressively the child became satisfactorily controlled. At the present moment the child continues to have mild hypotony and shows attention disorder and irritability. Melatonin has proven to be useful as adjunctive therapy in the clinical control of this case of severe infantile myoclonic epilepsy. The results suggest that melatonin may have a useful role in mechanisms of neuroprotection and also indicate its use in other cases of untreatable epilepsy. Further studies using more patients and placebo-treatment would be beneficial in understanding the potential use of melatonin as a co-therapy in some cases of seizures.

Original languageEnglish (US)
Pages (from-to)97-105
Number of pages9
JournalJournal of Pineal Research
Volume23
Issue number2
StatePublished - Sep 1997

Fingerprint

Myoclonic Epilepsy
Melatonin
Anticonvulsants
Seizures
Therapeutics
Phenobarbital
Electroencephalography
Vigabatrin
Clonazepam
Neurologic Examination
Glutamate Receptors
Valproic Acid
Neuroprotective Agents
Coma
Circadian Rhythm
Single-Photon Emission-Computed Tomography

Keywords

  • Anticonvulsant therapy
  • Infantile myoclonic epilepsy
  • Melatonin
  • Melatonin circadian rhythm
  • Phenobarbital

ASJC Scopus subject areas

  • Endocrinology

Cite this

Molina-Carballo, A., Muñoz-Hoyos, A., Reiter, R. J., Sánchez-Forte, M., Moreno-Madrid, F., Rufo-Campos, M., ... Acuña-Castroviejo, D. (1997). Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: Two years' experience. Journal of Pineal Research, 23(2), 97-105.

Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy : Two years' experience. / Molina-Carballo, Antonio; Muñoz-Hoyos, Antonio; Reiter, Russel J; Sánchez-Forte, Miguel; Moreno-Madrid, Francisco; Rufo-Campos, Miguel; Molina-Font, Juan Antonio; Acuña-Castroviejo, Darío.

In: Journal of Pineal Research, Vol. 23, No. 2, 09.1997, p. 97-105.

Research output: Contribution to journalArticle

Molina-Carballo, A, Muñoz-Hoyos, A, Reiter, RJ, Sánchez-Forte, M, Moreno-Madrid, F, Rufo-Campos, M, Molina-Font, JA & Acuña-Castroviejo, D 1997, 'Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: Two years' experience', Journal of Pineal Research, vol. 23, no. 2, pp. 97-105.
Molina-Carballo A, Muñoz-Hoyos A, Reiter RJ, Sánchez-Forte M, Moreno-Madrid F, Rufo-Campos M et al. Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: Two years' experience. Journal of Pineal Research. 1997 Sep;23(2):97-105.
Molina-Carballo, Antonio ; Muñoz-Hoyos, Antonio ; Reiter, Russel J ; Sánchez-Forte, Miguel ; Moreno-Madrid, Francisco ; Rufo-Campos, Miguel ; Molina-Font, Juan Antonio ; Acuña-Castroviejo, Darío. / Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy : Two years' experience. In: Journal of Pineal Research. 1997 ; Vol. 23, No. 2. pp. 97-105.
@article{8aa8851300974a69abcccdfedd028e0a,
title = "Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: Two years' experience",
abstract = "Recent data indicate that melatonin inhibits brain glutamate receptors and nitric oxide production, thus suggesting that it may exert a neuroprotective and antiexcitotoxic effect. Melatonin has been seen to prevent seizures in several animal models and to decrease epileptic manifestations in humans. The lack of response to conventional anticonvulsants in an epileptic child led us to use melatonin in this case. A female child who began to have convulsive seizures at the age of 1.5 months and was diagnosed as having severe myoclonic epilepsy was unsuccessfully treated with different combinations of anticonvulsants, including valproic acid, phenobarbital, clonazepam, vigabatrin, lamotrigin, and clobazam. Melatonin was thus added to the treatment. Imaging studies (CT, SPECT, and MNR), EEG recordings, blood biochemical, and hematological analyses, including measures of the circadian rhythm of melatonin, were made. The child was initially treated with various anticonvulsants. Severe neurological and psychomotor deterioration combined with increased seizure activity showed a lack of response to the treatment. At the age of 29 mon the patient was in a pre-comatose stage at which time melatonin was added to treatment. After 1 month of melatonin plus phenobarbital therapy and for a year thereafter, the child's seizures were under control. On reducing the melatonin dose after this time, however, seizures resumed and the patient's condition was re-stabilized after restoring melatonin. Prior to our attempts to reduce melatonin, all analyses, including EEG recordings and SPECT, were normal. As far as the results of neurological examination are concerned, only mild hypotony without focalization remained. Changes in the therapeuticschedules during the second year of melatonin treatment, including the withdrawal of phenobarbital, did not result in the same degree of seizure control, although progressively the child became satisfactorily controlled. At the present moment the child continues to have mild hypotony and shows attention disorder and irritability. Melatonin has proven to be useful as adjunctive therapy in the clinical control of this case of severe infantile myoclonic epilepsy. The results suggest that melatonin may have a useful role in mechanisms of neuroprotection and also indicate its use in other cases of untreatable epilepsy. Further studies using more patients and placebo-treatment would be beneficial in understanding the potential use of melatonin as a co-therapy in some cases of seizures.",
keywords = "Anticonvulsant therapy, Infantile myoclonic epilepsy, Melatonin, Melatonin circadian rhythm, Phenobarbital",
author = "Antonio Molina-Carballo and Antonio Mu{\~n}oz-Hoyos and Reiter, {Russel J} and Miguel S{\'a}nchez-Forte and Francisco Moreno-Madrid and Miguel Rufo-Campos and Molina-Font, {Juan Antonio} and Dar{\'i}o Acu{\~n}a-Castroviejo",
year = "1997",
month = "9",
language = "English (US)",
volume = "23",
pages = "97--105",
journal = "Journal of Pineal Research",
issn = "0742-3098",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy

T2 - Two years' experience

AU - Molina-Carballo, Antonio

AU - Muñoz-Hoyos, Antonio

AU - Reiter, Russel J

AU - Sánchez-Forte, Miguel

AU - Moreno-Madrid, Francisco

AU - Rufo-Campos, Miguel

AU - Molina-Font, Juan Antonio

AU - Acuña-Castroviejo, Darío

PY - 1997/9

Y1 - 1997/9

N2 - Recent data indicate that melatonin inhibits brain glutamate receptors and nitric oxide production, thus suggesting that it may exert a neuroprotective and antiexcitotoxic effect. Melatonin has been seen to prevent seizures in several animal models and to decrease epileptic manifestations in humans. The lack of response to conventional anticonvulsants in an epileptic child led us to use melatonin in this case. A female child who began to have convulsive seizures at the age of 1.5 months and was diagnosed as having severe myoclonic epilepsy was unsuccessfully treated with different combinations of anticonvulsants, including valproic acid, phenobarbital, clonazepam, vigabatrin, lamotrigin, and clobazam. Melatonin was thus added to the treatment. Imaging studies (CT, SPECT, and MNR), EEG recordings, blood biochemical, and hematological analyses, including measures of the circadian rhythm of melatonin, were made. The child was initially treated with various anticonvulsants. Severe neurological and psychomotor deterioration combined with increased seizure activity showed a lack of response to the treatment. At the age of 29 mon the patient was in a pre-comatose stage at which time melatonin was added to treatment. After 1 month of melatonin plus phenobarbital therapy and for a year thereafter, the child's seizures were under control. On reducing the melatonin dose after this time, however, seizures resumed and the patient's condition was re-stabilized after restoring melatonin. Prior to our attempts to reduce melatonin, all analyses, including EEG recordings and SPECT, were normal. As far as the results of neurological examination are concerned, only mild hypotony without focalization remained. Changes in the therapeuticschedules during the second year of melatonin treatment, including the withdrawal of phenobarbital, did not result in the same degree of seizure control, although progressively the child became satisfactorily controlled. At the present moment the child continues to have mild hypotony and shows attention disorder and irritability. Melatonin has proven to be useful as adjunctive therapy in the clinical control of this case of severe infantile myoclonic epilepsy. The results suggest that melatonin may have a useful role in mechanisms of neuroprotection and also indicate its use in other cases of untreatable epilepsy. Further studies using more patients and placebo-treatment would be beneficial in understanding the potential use of melatonin as a co-therapy in some cases of seizures.

AB - Recent data indicate that melatonin inhibits brain glutamate receptors and nitric oxide production, thus suggesting that it may exert a neuroprotective and antiexcitotoxic effect. Melatonin has been seen to prevent seizures in several animal models and to decrease epileptic manifestations in humans. The lack of response to conventional anticonvulsants in an epileptic child led us to use melatonin in this case. A female child who began to have convulsive seizures at the age of 1.5 months and was diagnosed as having severe myoclonic epilepsy was unsuccessfully treated with different combinations of anticonvulsants, including valproic acid, phenobarbital, clonazepam, vigabatrin, lamotrigin, and clobazam. Melatonin was thus added to the treatment. Imaging studies (CT, SPECT, and MNR), EEG recordings, blood biochemical, and hematological analyses, including measures of the circadian rhythm of melatonin, were made. The child was initially treated with various anticonvulsants. Severe neurological and psychomotor deterioration combined with increased seizure activity showed a lack of response to the treatment. At the age of 29 mon the patient was in a pre-comatose stage at which time melatonin was added to treatment. After 1 month of melatonin plus phenobarbital therapy and for a year thereafter, the child's seizures were under control. On reducing the melatonin dose after this time, however, seizures resumed and the patient's condition was re-stabilized after restoring melatonin. Prior to our attempts to reduce melatonin, all analyses, including EEG recordings and SPECT, were normal. As far as the results of neurological examination are concerned, only mild hypotony without focalization remained. Changes in the therapeuticschedules during the second year of melatonin treatment, including the withdrawal of phenobarbital, did not result in the same degree of seizure control, although progressively the child became satisfactorily controlled. At the present moment the child continues to have mild hypotony and shows attention disorder and irritability. Melatonin has proven to be useful as adjunctive therapy in the clinical control of this case of severe infantile myoclonic epilepsy. The results suggest that melatonin may have a useful role in mechanisms of neuroprotection and also indicate its use in other cases of untreatable epilepsy. Further studies using more patients and placebo-treatment would be beneficial in understanding the potential use of melatonin as a co-therapy in some cases of seizures.

KW - Anticonvulsant therapy

KW - Infantile myoclonic epilepsy

KW - Melatonin

KW - Melatonin circadian rhythm

KW - Phenobarbital

UR - http://www.scopus.com/inward/record.url?scp=0031226947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031226947&partnerID=8YFLogxK

M3 - Article

C2 - 9392448

AN - SCOPUS:0031226947

VL - 23

SP - 97

EP - 105

JO - Journal of Pineal Research

JF - Journal of Pineal Research

SN - 0742-3098

IS - 2

ER -